iXensor is chosen to be one of the 10 startups who can join the 2019 Merck Accelerator Program. Among 595 application all over the world, iXensor stands out by its innovative PixoTech technology which turns mobile devices into in vitro diagnostic platform.
Merck Accelerator Program aims to build sustainable partnerships with startups who owns visionary ideas and collaboration potential with them. The chosen startups will move in Merck Innovation Center in Darmstadt and start the three-month brainstorm with experts within the Merck network. “We can’t wait to exchange ideas with Merck experts from all over the world and find the perfect collaboration with them. It’s a significant milestone for us.” said Tung-Meng Tsai, CEO of iXensor.
iXensor’s innovative PixoTech technology turns mobile devices into in vitro diagnostic platform. They have applied the technology to chronic diseases management, women health management and infectious diseases management. Their innovative products– Eveline Ovulation Test and PixoTest POCT System have blown the world away. “We aim to make the quality healthcare accessible and timely. We’re proud that we have realized our ideas and provide the solutions that fit people’s need.” said Yen-Yu Chen, CTO of iXensor.
iXensor will bring their latest innovation, PixoTest POCT System, to Merck Innovation Center to see if there’s any collaboration potential with them. The promising startup stands on the shoulder of the giants will definitely spark more healthcare solutions to fit the world’s need.